Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model-Reference-Cited by-同舟云学术

Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model

Published:2013-02-26 Issue:5 Volume:12 Page:589-597
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Ninomiya Takashi,Takigawa Nagio,Ichihara Eiki,Ochi Nobuaki,Murakami Toshi,Honda Yoshihiro,Kubo Toshio,Minami Daisuke,Kudo Kenichiro,Tanimoto Mitsune,Kiura Katsuyuki

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer;Critical Reviews in Oncology/Hematology;2024-04

2. Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis;Frontiers in Oncology;2024-01-23

3. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

4. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations;Lung Cancer;2023-10

5. Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice;Frontiers in Pharmacology;2023-04-07